- Home
- KNOP vs ALT Comparison
KNOP vs ALT Comparison
Compare KNOP & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KNOP | ALT |
|---|---|---|
| Founded | 2013 | 1997 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 355.2M | 421.5M |
| IPO Year | 2012 | 2005 |
Fundamental Metrics
Financial Performance| Metric | KNOP | ALT |
|---|---|---|
| Price | $10.58 | $2.97 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | N/A | ★ $17.67 |
| AVG Volume (30 Days) | 43.9K | ★ 4.4M |
| Earning Date | 05-19-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.86% | N/A |
| EPS Growth | N/A | ★ 25.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,000.00 |
| Revenue This Year | $3.51 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.00 | ★ N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $6.96 | $2.56 |
| 52 Week High | $11.78 | $6.44 |
Technical Indicators
Market Signals| Indicator | KNOP | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 51.55 | 51.63 |
| Support Level | $10.03 | $2.87 |
| Resistance Level | $10.93 | $3.09 |
| Average True Range (ATR) | 0.36 | 0.13 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 41.75 | 48.81 |
Price Performance
Historical ComparisonAbout KNOP KNOT Offshore Partners LP
KNOT Offshore Partners LP owns, operates, and shuttles tankers under long-term charters in the North Sea and Brazil. The company provides crude oil loading, transportation, and storage services under time charters and bareboat charters. The Partnership is formed for acquiring ownership interests in over four shuttle tankers owned by Knutsen NYK Offshore Tankers AS (KNOT). It operates through the shuttle tanker market segment.
About ALT Altimmune Inc.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.